Every few months, a new documentary resurfaces what’s now a familiar headline: microplastics in our brains, forever chemicals in our blood, plasticizers in our babies’ umbilical cords. The response from the wellness world is just as familiar — a cleanse, a tincture, a binder, a 30-day detox protocol.
And the people who are suffering the most — chronic gut issues, unexplained infertility, brain fog, fatigue, mysterious inflammation — keep doing these protocols. And keep not getting better.
That’s not a moral failure. It’s not a discipline problem. It’s a biology problem that almost no one is explaining correctly.
The problem isn’t that your body doesn’t know how to detoxify these compounds. It does. Human biochemistry has a deeply sophisticated, multi-stage system for neutralizing and eliminating synthetic chemicals. The problem is that this system requires a specific biological capacity to run — and the very chemicals you’re trying to clear are damaging the machinery that’s supposed to clear them.
In other words: you can’t detox with a broken detox system. And when you try, you often make things worse.
This article is about what’s actually happening in your biology — not what to take. Because the protocol is individual. But the mechanism is universal, and once you understand it, the right approach for your biology becomes a question you can actually answer.
Three separate problems, not one
Most of the conversation collapses “plastics” into a single category. It’s actually three distinct classes of compounds, each causing damage through different pathways:
Microplastics and nanoplastics — physical particles less than 5mm (micro) or less than 1μm (nano). These cause direct mechanical damage to tissues, act as surface rafts carrying other toxins across biological barriers, and nucleate pathological protein aggregation in the brain.
Plasticizers — BPA, phthalates (DEHP, DBP, BBP), and related compounds that leach out of plastic. These are classical endocrine disruptors with relatively short half-lives — which sounds reassuring until you realize we’re re-exposed multiple times a day.
PFAS — “forever chemicals” — perfluoroalkyl and polyfluoroalkyl substances like PFOA, PFOS, PFHxS. These are the worst of the three. They’re not metabolized by the body at all. They have biological half-lives measured in years, not days. They bioaccumulate. And they hijack the very transport systems your body uses to eliminate waste.
Any framework that treats these three as one thing will fail on at least two of them. They need different biological capacities activated in different sequences.
The gut takes the first — and worst — hit
The gastrointestinal tract is where exposure concentrates, where the mucosal immune system meets the outside world, and where most of these chemicals either get neutralized or enter circulation. It’s also where the damage cascade starts.
When microplastics enter the gut, several things happen simultaneously. The mucin layer — that protective gel coat separating your gut bacteria from your epithelial cells — gets thinned and disrupted. The loss of Akkermansia muciniphila, a keystone species that paradoxically maintains the mucus layer, is one of the most consistent findings across studies. Firmicutes-to-Bacteroidetes ratios shift. Pathogenic and opportunistic species expand into the vacated niches.
Then the tight junctions between your intestinal cells — the proteins ZO-1, occludin, and claudin-3 that keep your gut wall sealed — get degraded. This is the real biology of “leaky gut.” Once that barrier is compromised, bacterial lipopolysaccharide (LPS) translocates into circulation, activating TLR4 receptors system-wide and driving the low-grade chronic inflammation that underlies most of modern chronic disease.
Short-chain fatty acid production collapses at the same time. Butyrate — the fuel your colonocytes require to stay alive — drops. And here’s where this becomes a compounding failure: colonocytes, unlike most cells, preferentially burn butyrate through mitochondrial beta-oxidation. When butyrate drops and mitochondrial function is simultaneously being damaged by the same toxins, the cells that are supposed to defend the gut barrier lose the energy to do their job.
This is the bioenergetic collapse at the center of my Host Capacity Model. The toxins don’t just cause inflammation — they cause a specific form of mitochondrial failure in the cells whose job is to keep them out. Once that’s established, every additional exposure does more damage than the one before.
There’s a second compounding loop in the gut that almost no one talks about. Bacterial beta-glucuronidase — an enzyme produced by certain gut species, elevated in dysbiosis — cleaves the glucuronide tags that your liver attached to toxins and hormones during phase II detoxification. The conjugate was supposed to leave the body. Instead, the bacteria pull the tag off, and the now-free toxin gets reabsorbed into portal circulation. Estrogens, BPA, phthalate metabolites, pharmaceuticals, heavy metals bound to bile — all recycled. Dysbiosis isn’t just a gut problem. It’s a whole-body detox failure.
The hormonal hijacking
This is the Netflix angle — and it’s real.
BPA binds directly to estrogen receptors ERα and ERβ at nanomolar affinities, meaning it activates estrogen signaling at concentrations vastly lower than what most people assume is “safe.” In men, it interferes with luteinizing hormone binding in the Leydig cells of the testes, which is the trigger that normally tells those cells to make testosterone. It also disrupts INSL3, the hormone responsible for testicular descent in fetal development — which is why BPA exposure during pregnancy is associated with cryptorchidism in male offspring.
Phthalates — particularly DEHP and its metabolite MEHP — work through a different mechanism but arrive at similar destinations. They suppress StAR protein, which is the cholesterol transporter that moves cholesterol into mitochondria for steroid hormone synthesis. Without StAR, testosterone production drops at the source. In women, phthalates induce oxidative stress within ovarian follicles and accelerate follicular atresia, reducing ovarian reserve. Men in the highest quartile of urinary phthalate metabolites have roughly 12% lower serum testosterone than the lowest quartile.
PFAS add a third layer: they activate PPARα and PPARγ, nuclear receptors that regulate lipid metabolism, steroidogenesis, and thyroid signaling. The downstream effect is disrupted hormone synthesis at multiple tissue sites simultaneously — gonads, thyroid, adrenals, pancreas.
And the most concerning finding isn’t the effect on the exposed individual. It’s the transgenerational epigenetic inheritance. Phthalate exposure can methylate the ESR1 promoter — the estrogen receptor 1 gene — in ways that carry across generations. BPA exposure alters methylation at over a thousand transposon regions in the human genome. The exposed mother isn’t just damaging her own biology; she’s rewriting her children’s hormone-receptor programming.
This is what the fertility crisis looks like at the molecular level. It’s not mysterious. It’s not unexplained. It’s chemistry.
The brain infiltration
The 2025 Nihart et al. study in Nature Medicine did something that hadn’t been done before: it quantified microplastics in human brain tissue from autopsy samples. Every brain had them. The concentrations had been climbing over time. And in the brains of people who had been diagnosed with dementia, microplastic concentrations were up to 10 times higher than in controls.
The mechanism of entry mirrors the gut: nanoparticles compromise the blood-brain barrier through ROS-mediated degradation of the exact same tight junction proteins — ZO-1, occludin, claudin. Once inside, they accumulate preferentially in fat-rich tissues, which is why the myelin sheath of neurons becomes a primary storage site.
The downstream damage operates through four converging pathways. First, mitochondrial ROS production inside neurons inhibits Complex I of the electron transport chain — the same biochemistry we see with Parkinson’s toxins like MPTP and rotenone. Second, microglial activation shifts from protective to pro-inflammatory, with NLRP3 inflammasome engagement and chronic cytokine release. Third, the particles themselves serve as physical scaffolds that nucleate amyloid-β and α-synuclein aggregation — seeding the exact protein misfolding events that drive Alzheimer’s and Parkinson’s. Fourth, the same particles carry heavy metals and persistent organic pollutants across the now-compromised BBB, amplifying every one of the above effects.
Tyrosine hydroxylase, the rate-limiting enzyme for dopamine synthesis, drops. Acetylcholinesterase is inhibited. Synaptic function degrades.
The brain fog, the anxiety, the depressed mood, the slowed cognition that everyone reports — this is the biology behind it. These aren’t psychological symptoms in search of a cause.
Why most detox protocols fail: the PFAS recirculation trap
Here’s the part that explains almost every failed detox attempt.
PFAS aren’t metabolized. The liver doesn’t break them down. What the liver does is secrete them into bile — which seems like a win, until you understand what happens next.
PFAS share structural features with bile acids. They’re amphipathic. They’re charged at physiological pH. They bind proteins similarly. And critically, they’re recognized as bile-acid-like substrates by the same transporters your body uses to recycle bile acids: NTCP in the liver, OATP1B1 and OATP2B1 in the enterocytes, ASBT at the apical membrane of the terminal ileum.
In human studies, biliary clearance of PFOA and PFOS is dozens of times higher than urinary clearance — meaning the liver is actively trying to dump them. But 89–97% of what gets dumped into the intestine is reabsorbed right back into portal circulation. The kidneys reabsorb them too, via organic anion transporters in the proximal tubule.
This is enterohepatic recirculation, and it’s why PFOS has a half-life of 2.7–5 years, why PFHxS approaches 8 years, and why virtually every American tested has detectable PFAS in serum.
And it’s why sauna, sweating, generic “cleanses,” most binders, juice protocols, and supplement stacks don’t move the needle on PFAS. None of them address the recirculation loop. You can push the liver to excrete more, but if 95% of what you excrete gets reabsorbed, you’re not reducing body burden. You’re just adding a metabolic tax.
The mechanistic principle that does work is interrupting the loop — preventing the bile-acid-bound PFAS from being reabsorbed in the small intestine and letting them leave in stool instead. Clinical trials in highly exposed populations have demonstrated 38–63% reductions in serum PFAS over 12 weeks when this principle is applied correctly. That’s the proof-of-concept: the biology is addressable, but only when the approach matches the mechanism.
Almost every other intervention sits upstream or downstream of the actual leak point.
What the body actually needs: capacity
This is the reframe. The body already has the machinery. What it needs is the capacity to run it.
Human detoxification is a three-phase system, and it only works if all three phases — plus supporting infrastructure — are running simultaneously.
Phase I (cytochrome P450 enzymes) oxidizes the parent compound. This step produces reactive intermediates and requires NADPH — a reducing cofactor whose availability is entirely dependent on mitochondrial and pentose phosphate pathway function.
Phase II conjugation attaches a water-soluble handle to those reactive intermediates: glucuronide (via UGTs), sulfate (via SULTs), glutathione (via GSTs), acetyl groups (via NATs), or methyl groups (via methylation pathways that depend on SAMe, MTHFR, B12, and folate). Every one of these reactions consumes ATP and specific cofactors that the body has to manufacture continuously.
Phase III transport uses ATP-dependent pumps — MRP2, BCRP, P-glycoprotein — to move the conjugated molecules out of cells and into bile or urine. Without functional phase III, phase II conjugates accumulate inside cells and cause damage instead of leaving.
Bile flow requires taurine or glycine conjugation of bile acids, adequate phosphatidylcholine secretion, and unobstructed flow from canaliculi to duodenum. Any degree of cholestasis closes the elimination route for fat-soluble toxins.
Gut barrier integrity is what keeps the conjugates from getting hydrolyzed by bacterial beta-glucuronidase and reabsorbed. A compromised barrier turns phase II into a round-trip.
Nrf2 is the master switch for the entire phase II system. When activated, it upregulates GSTs, UGTs, NQO1, HO-1, glutathione synthesis enzymes, and antioxidant defenses. When suppressed — by chronic inflammation, mitochondrial dysfunction, or persistent oxidative stress — the entire downstream apparatus underperforms.
Renal function determines whether water-soluble conjugates leave the body at all.
Every single one of these steps is mitochondrially dependent. This isn’t rhetorical. Phase II conjugation cannot happen without ATP. Glutathione cannot be synthesized without ATP and NADPH. Nrf2 signaling is calibrated by mitochondrial redox state. Bile acid synthesis is driven by hepatocyte mitochondrial function. The entire detoxification architecture is built on the bioenergetic foundation that the electron transport chain provides.
And the toxins themselves damage that foundation. PFAS activate PPARα abnormally and directly inhibit Complex I. Microplastics generate mitochondrial ROS that oxidize the inner membrane and disrupt electron flow. Plasticizers interfere with mitochondrial biogenesis and membrane potential. The more exposure accumulates, the less capacity remains to handle the next exposure. This is the closed loop at the heart of the problem, and it has to be broken from outside the system.
The genetic layer: why some people are sinks
Two people with identical exposure can have completely different trajectories. That’s not random. It’s toxicogenomic stratification.
A few variants matter more than others:
GSTM1 and GSTT1 null polymorphisms are complete deletions of two glutathione transferase genes. Present in 20–50% of the population depending on ethnicity. These individuals literally have no enzyme to conjugate glutathione to certain electrophiles — the reactive intermediates produced by phase I have nowhere to go.
GSTP1 Ile105Val (rs1695) reduces activity against a different class of electrophiles, including those derived from polycyclic aromatic hydrocarbons and oxidized lipids.
UGT1A1*28, the Gilbert’s syndrome variant, cuts glucuronidation capacity by 30–40% in approximately 10% of people. Impaired glucuronidation affects BPA clearance, estrogen metabolism, bilirubin, and a large number of pharmaceuticals.
MTHFR C677T and A1298C throttle the folate-methionine cycle, reducing SAMe production. Since SAMe is the methyl donor for COMT (which metabolizes catecholamines and estrogens), for methyltransferases that methylate phase II substrates, and for maintaining mitochondrial DNA integrity, MTHFR variants compound impairment across multiple systems simultaneously.
PON1 Q192R, L55M, and C-108T variants determine paraoxonase activity, which handles oxidized lipids, organophosphate metabolites, and certain homocysteine derivatives. Low-PON1 status is associated with increased susceptibility to pesticide toxicity and neurodegeneration.
SULT1A1 polymorphisms affect sulfation — a major route for BPA, estrogens, thyroid hormones, and catecholamines.
NQO1 C609T reduces quinone detoxification, leaving reactive quinones to damage proteins and DNA.
NFE2L2 SNPs reduce the responsiveness of Nrf2 itself — meaning even the master switch doesn’t turn on as strongly when it needs to.
SLCO1B1 variants affect the hepatic OATP transporter that moves PFAS and similar organic anions into hepatocytes for processing.
CYP1A2, CYP2E1 variants shift phase I kinetics, changing how fast parent compounds are oxidized into reactive intermediates — which matters because fast oxidation without matching phase II capacity produces a bottleneck of reactive metabolites that cause more damage than the original toxin.
An individual carrying multiple impaired variants is a genetic sink for these compounds. They accumulate more, clear less, and suffer worse at any given exposure level. That’s why one spouse develops autoimmune disease, infertility, or early cognitive decline while the other — same water, same food, same house — stays relatively well. It’s not luck. It’s the interaction between universal exposure and individual capacity.
The sequence, and why mobilizing without capacity makes things worse
The biology gives you a natural sequence. It’s not a protocol. It’s the order in which the system actually works when you’re trying to restore function.
The first focus is always reducing the inflow. Continuing to add new exposure while trying to clear the old is a losing equation regardless of what else you do.
The second focus is rebuilding capacity before mobilizing anything. This means restoring mitochondrial function, glutathione synthesis, methylation capacity, bile flow, and gut barrier integrity. Every downstream step fails without these. Pushing a detox without this foundation is a common and predictable reason people get worse rather than better.
The third focus is upregulating phase II throughput. Nrf2 activation, broadening the enzymatic bandwidth of conjugation, and ensuring the handoff from phase I to phase II is tight enough that reactive intermediates don’t accumulate and cause oxidative damage.
The fourth focus is specifically interrupting the recirculation loops — bile acid reuptake for PFAS and lipophilic toxins, and beta-glucuronidase deconjugation for hormone metabolites and phase II conjugates. Without this, you’re running a pump with the drain closed.
The fifth focus is mobilization through the excretory routes — skin, lymphatic flow, urinary elimination. This is the step most people jump to first. When they do it without the upstream capacity in place, the result is predictable: stored toxins get released from adipose tissue into circulation, find no waiting conjugation capacity, and redistribute to other lipid-rich tissues — the brain, bone marrow, breast tissue. There’s a documented version of this in the PFAS literature: maternal caloric restriction mobilizes stored PFAS into breast milk, exposing infants. Mobilization without clearance isn’t detoxification. It’s redistribution. It can make things substantially worse, particularly for people whose genetic or mitochondrial capacity is already impaired.
The sixth focus is hormonal and epigenetic recovery — rebalancing estrogen metabolism pathways, restoring depleted endocrine axes, and supporting repair of the methylation patterns that got disrupted in the first place.
The specific work within each focus is entirely individual. Someone with severe mitochondrial dysfunction starts in a different place than someone with intact mitochondria and impaired methylation. Someone with GSTM1 deletion needs a different phase II strategy than someone with intact glutathione transferases. Someone with elevated beta-glucuronidase needs work in a different place than someone with sluggish bile flow. The biology is the same. The entry point and the sequence of emphasis are not.
There is no generic answer to any of this. The people who try to sell one either don’t understand the biology or are hoping you don’t.
The reframe
Exposure is universal. Capacity is individual.
Everyone has microplastics in their blood. Everyone has PFAS in their serum. Everyone has measurable phthalate metabolites in their urine. The question isn’t whether you’re exposed. The question is whether your body can still process what it’s being asked to process — and whether the machinery that’s supposed to do that processing is still intact.
For some people, it is. For many people — especially those who’ve been chronically ill for years, who have unfavorable genetic variants, who have underlying mitochondrial dysfunction or gut barrier disruption — it isn’t. And for those people, generic detox protocols aren’t just ineffective. They can be actively harmful.
The right approach starts by mapping the individual biology: genetic polymorphisms, mitochondrial function, gut barrier integrity, phase II bandwidth, hormonal status, and the actual measured body burden of the compounds in question. Then it sequences the work to rebuild capacity before attempting mobilization. Then it addresses the specific loops — particularly enterohepatic recirculation and beta-glucuronidase deconjugation — that ordinary protocols never touch.
That’s the work. The approach is built for the person, not the other way around.
If you’re dealing with chronic symptoms you suspect are tied to environmental exposure — gut dysfunction, unexplained fatigue, hormonal disruption, brain fog, or any of the multi-system patterns described above — and you want a case analysis grounded in your specific biology rather than a templated protocol, consultations are available. The process includes a comprehensive case review, a one-on-one session, and a written summary mapping your individual capacity profile and the staged plan that follows from it. Reach out at research@biomelogic.net.